CIK 1615982
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 93.92% | 31 |
| Unclassified | 6.08% | 2 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics, Inc. | Health Care | 26.68% |
| 2 | ERAS | Erasca, Inc. | Health Care | 9.89% |
| 3 | ORKA | Oruka Therapeutics, Inc. | Health Care | 7.60% |
| 4 | SYRE | Spyre Therapeutics, Inc. | Health Care | 6.94% |
| 5 | KALVISTA PHARMACEUTICALS INC | Unclassified | 4.86% | |
| 6 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Health Care | 3.70% |
| 7 | DMRA | Damora Therapeutics, Inc. | Health Care | 3.48% |
| 8 | OCUL | OCULAR THERAPEUTIX, INC | Health Care | 3.27% |
| 9 | COGT | Cogent Biosciences, Inc. | Health Care | 2.87% |
| 10 | VRDN | Viridian Therapeutics, Inc.\DE | Health Care | 2.83% |
31/33 names classified · sector 93.9% of weight · industry 93.9% · mkt cap 93.1%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 93.9% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/32 names) · unclassified 100.0%: APGE, ERAS, ORKA, SYRE, , DNTH, DMRA, OCUL, COGT, VRDN +22 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | APGEAPOGEE THERAPEUTICS INC | 8,493,321 | $715M | 26.7% | HOLD |
| 2 | ERASERASCA INC | 16,382,812 | $265M | 9.9% | TRIM −8% |
| 3 | ORKAORUKA THERAPEUTICS INC | 4,148,428 | $203M | 7.6% | HOLD |
| 4 | SYRESPYRE THERAPEUTICS INC | 3,685,448 | $186M | 6.9% | HOLD |
| 5 | KALVISTA PHARMACEUTICALS INC | 6,474,485 | $130M | 4.9% | TRIM −4% |
| 6 | DNTHDIANTHUS THERAPEUTICS INC | 1,180,000 | $99M | 3.7% | ADD 18% |
| 7 | DMRADAMORA THERAPEUTICS INC | 3,603,595 | $93M | 3.5% | NEW |
| 8 | OCULOCULAR THERAPEUTIX INC | 10,346,926 | $88M | 3.3% | ADD 41% |
| 9 | COGTCOGENT BIOSCIENCES INC | 2,000,000 | $77M | 2.9% | HOLD |
| 10 | VRDNVIRIDIAN THERAPEUTICS INC | 3,882,709 | $76M | 2.8% | HOLD |
| 11 | SVRASAVARA INC | 13,740,375 | $75M | 2.8% | HOLD |
| 12 | ELVNENLIVEN THERAPEUTICS INC | 1,726,331 | $68M | 2.5% | TRIM −46% |
| 13 | ORICORIC PHARMACEUTICALS INC | 4,319,765 | $55M | 2.0% | TRIM −24% |
| 14 | VORVOR BIOPHARMA INC | 3,041,719 | $54M | 2.0% | ADD 56% |
| 15 | MAZEMAZE THERAPEUTICS INC | 1,602,034 | $48M | 1.8% | ADD 3% |
| 16 | CTMXCYTOMX THERAPEUTICS INC. | 9,982,124 | $47M | 1.8% | TRIM −36% |
| 17 | JBIOJADE BIOSCIENCES INC | 3,220,364 | $45M | 1.7% | HOLD |
| 18 | DYNDYNE THERAPEUTICS INC | 2,173,913 | $39M | 1.5% | HOLD |
| 19 | CBIOCRESCENT BIOPHARMA INC. | 2,133,576 | $39M | 1.5% | HOLD |
| 20 | ZURAZURA BIO LTD | 6,434,990 | $38M | 1.4% | ADD 20% |
| 21 | RLMDRELMADA THERAPEUTICS INC | 4,843,380 | $34M | 1.3% | NEW |
| 22 | ENGENE HOLDINGS INC | 4,771,414 | $32M | 1.2% | HOLD |
| 23 | TENXTENAX THERAPEUTICS INC | 1,675,262 | $27M | 1.0% | NEW |
| 24 | ANLADLAI NORTYE LTD | 3,212,731 | $22M | 0.8% | NEW |
| 25 | IPSCCENTURY THERAPEUTICS INC | 8,695,652 | $20M | 0.7% | NEW |
| 26 | CGEMCULLINAN THERAPEUTICS INC | 1,379,965 | $20M | 0.7% | HOLD |
| 27 | HELPCYBIN INC | 3,851,654 | $18M | 0.7% | HOLD |
| 28 | SRZNSURROZEN INC | 632,931 | $18M | 0.7% | HOLD |
| 29 | SEPNSEPTERNA INC | 506,056 | $12M | 0.5% | TRIM −17% |
| 30 | KRROKORRO BIO INC | 1,009,500 | $11M | 0.4% | NEW |
| 31 | ANROALTO NEUROSCIENCE INC | 500,000 | $11M | 0.4% | NEW |
| 32 | ARTVARTIVA BIOTHERAPEUTICS INC | 1,609,569 | $10M | 0.4% | HOLD |
| 33 | XFORX4 PHARMACEUTICALS INC | 330,525 | $1M | 0.1% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| APGEAPOGEE THERAPEUTICS INC | 8.5M | 8.5M | 8.5M | 8.5M | 8.5M | 8.5M | $715M |
| ERASERASCA INC | 16.2M | 16.2M | 17.9M | 17.9M | 17.9M | 16.4M | $265M |
| ORKAORUKA THERAPEUTICS INC | 3.3M | 4.1M | 4.1M | 4.1M | 4.1M | 4.1M | $203M |
| SYRESPYRE THERAPEUTICS INC | 2.7M | 2.7M | 2.7M | 2.7M | 3.7M | 3.7M | $186M |
| KALVISTA PHARMACEUTICALS INC | 6.2M | 6.7M | 6.7M | 6.7M | 6.7M | 6.5M | $130M |
| DNTHDIANTHUS THERAPEUTICS INC | 1.7M | 1.7M | 1.0M | 961K | 1.0M | 1.2M | $99M |
| DMRADAMORA THERAPEUTICS INC | — | — | — | — | — | 3.6M | $93M |
| OCULOCULAR THERAPEUTIX INC | 12.8M | 12.8M | 12.8M | 13.2M | 7.3M | 10.3M | $88M |
| COGTCOGENT BIOSCIENCES INC | 5.7M | 5.7M | 4.8M | 4.0M | 2.0M | 2.0M | $77M |
| VRDNVIRIDIAN THERAPEUTICS INC | 3.9M | 3.9M | 3.9M | 3.9M | 3.9M | 3.9M | $76M |
| SVRASAVARA INC | — | 3.3M | 8.9M | 12.7M | 13.7M | 13.7M | $75M |
| ELVNENLIVEN THERAPEUTICS INC | 4.0M | 4.0M | 4.0M | 3.2M | 3.2M | 1.7M | $68M |
| ORICORIC PHARMACEUTICALS INC | 4.4M | 3.2M | 6.6M | 6.6M | 5.7M | 4.3M | $55M |
| VORVOR BIOPHARMA INC | — | — | — | 500K | 1.9M | 3.0M | $54M |
| MAZEMAZE THERAPEUTICS INC | — | — | — | 1.2M | 1.5M | 1.6M | $48M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
